LETROZOLE for PCOS
In infertile women with PCOS, letrozole was associated with higher ovulation rates and greater likelihood of live birth and singleton pregnancy compared with clomiphene citrate.
Hypothesized mechanism
Letrozole, an aromatase inhibitor, induces ovulation more effectively than the SERM clomiphene citrate in PCOS.
This is the model’s proposed mechanism from the sources on file, not a demonstrated causal pathway. How well the published record supports it is reflected in the rigor and plausibility dimensions of the score, and traced to the verbatim sources at the foot of the page.
How the score was reached, for this pair
The composite score is the sum of five dimensions, each scored 0 to 2 by the model from the evidence on file. Below is the sub-score this specific pair received on each, with what that dimension measures. It scored 8 of 10 overall, a strong reading, from a direct rated strong in strength.
The model’s overall reasoning for this pair is the summary at the top of the page, and the mechanism it proposed is in the section above.
Scored for women. Evidence generated in women (female population, ~100% female). (band F1, ×1.00).
Corroboration
All three claims derive from a single source ('Pregnancy in Polycystic Ovary Syndrome II'), which appears to be one RCT (PPCOS II trial). A single primary study provides limited corroboration; no independent replication is shown. The claims are internally consistent but come from one study.
Rigor
The source describes a controlled trial comparing letrozole to clomiphene citrate with hypothesis-driven outcomes (live birth, ovulation, singleton pregnancy), consistent with an RCT design, which scores 2.
Specificity
Both the drug (letrozole) and the condition (PCOS) are explicitly named in all claims, e.g. 'ovulation induction with an aromatase inhibitor (letrozole)... in infertile women with PCOS.'
Plausibility
The claims identify letrozole as an aromatase inhibitor used for ovulation induction, contrasting with clomiphene as a SERM, suggesting a plausible mechanism via ovulation. However, the mechanism is only implied, not directly evidenced with data in these claims.
Consistency
Three outcomes (live birth, singleton pregnancy, ovulation rate) all point in the same direction favoring letrozole over clomiphene, showing consistent directionality across endpoints within the source.
Independent reading, reported beside the score
One outside model cross-reference is reported alongside the composite score. It is recorded separately and is not combined into the score.
MATRIX cross-reference
Every Cure’smachine-learned treatment-probability model, drawn from a biomedical knowledge graph across roughly 1,800 drugs and 22,000 diseases. It provides a model-based estimate of how plausible a drug-disease link is given the structure of biomedical knowledge, reported alongside the substrate’s own evidence.
For this pair. MATRIX maps this drug and disease in its graph but returned no treat-score for the pair, which can mean the predicted link fell below the model's publication threshold.
Scored over MATRIX’s own entities, confirming the same drug and disease: CHEBI:6413 (drug) and MONDO:0008487 (disease). Validate against the source: Every Cure’s MATRIX dataset ↗.
More on the MATRIX cross-reference and its provenance →Layers not covered for this pair
Not covered for this pair. This layer holds documented sex-specific pharmacokinetics for a limited set of drugs, and this compound is not among them yet. A blank here means the drug is not covered by the layer, not that no sex difference exists.
More on the sex-specific pharmacokinetics layer and its sources →Not covered for this pair. The cycle-phase layer is seeded for the strongest-evidence cases so far (PMDD), and this pair is not among them yet. A blank here means the pair is not covered by the layer, not that the effect was found to be phase-independent.
More on the cycle-phase layer and its sources →Source evidence · what the pipeline ingested
These are the sources the pipeline ingested to detect and score this signal, the published literature the model actually read, each tagged by study type. Where the model combined findings the claim is marked as a synthesis (S), and where the literature disagrees the contradiction is shown (!).
Every source below belongs to this signal’s evidence arm, Direct research. Whel reads each drug-condition pair through four such arms, each held to its own inclusion bar; a signal is surfaced through one of them.
- 1ovulation induction with an aromatase inhibitor (letrozole) is more likely to result in live birth than ovulation induction with a selective estrogen receptor modulator (clomiphene citrate) in infertile women with PCOS ClinicalTrials.gov · NCT00719186 ↗
- 2Treatment with letrozole is more likely to result in singleton pregnancy compared to treatment with clomiphene citrate. ClinicalTrials.gov · NCT00719186 ↗
- 3Treatment with letrozole is more likely to result in ovulation (increased ovulation rate) compared to treatment with clomiphene citrate. ClinicalTrials.gov · NCT00719186 ↗
- 4Treatment with letrozole will less likely result in a first trimester intrauterine fetal demise than treatment with clomiphene citrate. ClinicalTrials.gov · NCT00719186 ↗
These are the verbatim sources the pipeline surfaced and read; they may not be the full published record for a pair, and the score reflects the strength and agreement of the evidence rather than its volume. The strength of these source types is what the rigor dimension of the score reads off. MATRIX, sex-specific pharmacokinetics, and cycle phase are separate layers the pipeline does not ingest, external cross-references reported beside the score, and they link to their own sources in their sections above.
The primary sources and pipelines this evidence is drawn from →